PIPELINE
Marketed Products
Two innovative therapies utilizing Kala’s proprietary AMPPLIFY® Drug Delivery Technology to address medical needs for front of the eye
First and only prescription therapy specifically for the short-term management
of the signs and symptoms of dry eye disease
First and only BID corticosteroid indicated for the treatment of post-operative ocular inflammation and pain
Development Pipeline
Proprietary development programs targeted to address front and back of the eye diseases
| Product Candidate* | Classification | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
|
KPI-012: Mesenchymal Stem Cell (MSC) Secretome Persistent Corneal Epithelial Defect (PCED)(Phase 1) |
Biologic | ||||
|
KPI-287: Tyrosine Kinase Inhibitor Retinal diseases, including wet AMD, DME, and RVO (Preclinical) |
NCE | ||||
|
Selective Glucocorticoid Receptor Modulator (SEGRM) Retinal diseases, including wet AMD, DME, and RVO; ocular surface diseases (Preclinical) |
NCE |
*Product candidates are investigational and have not been approved by any regulatory authority.
NCE – New Chemical Entity
